News - Page 124

TLDR: Manchester-based tech startup VSim, founded by ex-Nvidia engineers, is raising funding from EQT Ventures. The startup focuses on simulation infrastructure for computing, targeting robotics and VFX markets. A Manchester-based tech startup

TLDR: Venture capital firm Lightbox considers a $100 million continuation fund to back mature startups like Rebel Foods and Furlenco. Continuation funds provide an exit for limited partners while allowing investment firms

TLDR: Rhizome, a startup backed by Looking Glass, raises $1 million in a seed round from San Francisco-based Convective Capital. They launch a new product, gridFirm, to help utilities in the United

TLDR: Investment manager Juan Delgado-Moreira reveals that the super-rich are increasingly investing in private markets due to their outperformance compared to public markets. Private market assets include real estate, private equity, venture

TLDR: Lanchi Ventures transitions after parting ways with BlueRun, expands to Hong Kong to connect Chinese AI entrepreneurs with global markets Focusing on sectors like AI, 3D interactive technologies, and robotics, Lanchi

TLDR: Antheia, a pharmaceutical ingredient manufacturer based in Menlo Park, CA, raised $17M in funding. The funding included a non-dilutive two-year project agreement up to $11M through the BioMaP Consortium. Antheia, led

TLDR: GRO Biosciences, a biotechnology company, raised $60.3M in Series B funding led by Atlas Venture and Access Biotechnology. The company plans to use the funds to advance its lead program for

TLDR: North Sky Capital raised $250 million for its impact secondaries fund, Clean Growth VI. The fund aims to generate strong private equity returns while creating positive environmental and social benefits. North

TLDR: Aven, a fintech company offering home equity-backed credit cards, reaches unicorn status with a US$142m Series D funding round led by Khosla Ventures and General Catalyst. Founded in 2019 by former

TLDR: Cell BioEngines, Inc. secures an additional $2 million in funding from SOSV and Empire State Development’s New York Ventures. The funding will support the company’s first multicenter clinical trial aimed at